anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: The objective is to explore the correlation between rectal swab culture and the overall 30-d survival of hematologic patients diagnosed with carbapenem-resistant organism (CRO) bloodstream infection.
METHODS: A total of 434 haematological patients who were complicated with Gram-negative bacilli (GNB) bloodstream infections (BSIs) caused by Gram-negative bacteria between January 2020 and December 2021 were included in our retrospective study. Based on their drug susceptibility results, we classified patients into CRO BSIs and non-CRO BSIs cases. Through group comparison, to uncover the correlation between the positive screening of rectal swabs and reducing the mortality of CRO BSI in patients with haematological diseases.
RESULTS: Among the 434 cases of Gram-negative bacteria bloodstream infection, 96 were identified as carbapenem-resistant bloodstream infection, which consisted of 57 cases of carbapenem-resistant Klebsiella pneumoniae (CR-KP), 19 cases of carbapenem-resistant Pseudomonas aeruginosa (CR-PA), 11 cases of carbapenem-resistant Escherichia coli (CR-CO), 5 cases of carbapenem-resistant Acinetobacter baumannii (CR-AB), and 4 cases of other Enterobacteriaceae. Before the onset of CRO bloodstream infection, rectal swab cultures were conducted on 36 patients, and the positive result rate was 75.0% (27/36), with 20 cases of CR-KP, 6 cases of CR-CO, and one case of carbapenem-resistant Enterobacter cloacae. It was observed that the rectal and blood cultures had matching outcomes in 75.0% of cases. The mortality rate within 30 d for CRO BSIs was 53.1% (51/96), while for carbapenem-resistant Enterobacteriaceae (CRE) BSIs it was 62.5% (45/72). Univariate analysis showed that 30-d mortality was significantly reduced when there were positive rectal culture results preceding bloodstream infection (P < 0.001), as well as preemptive anti-infection treatment (P < 0.001). Multivariate analysis demonstrated that preemptive adjustment to an effective antibiotic regimen, guided by positive rectal culture results, had a significant effect on decreasing 30-d mortality following CRO BSIs (P= 0.002). Furthermore, for the management of CRE BSIs, antibiotic treatments utilising ceftazidime/avibactam (CAV/AVI) may be more beneficial compared to those that use tigecycline (TGC) or polymyxin (PMB).
CONCLUSION: CRO BSI, especially CRE BSI, can be life-threatening for those with haematological diseases. Utilising rectal culture can effectively identify CRO strains with high sensitivity and specificity. Adjusting antibiotic treatment based on the preemptive positive rectal culture results may significantly decrease 30-d mortality rates for haematological patients with CRO BSIs.
Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
TOP2 inhibitors (TOP2i) are effective drugs for breast cancer treatment. However, they can cause cardiotoxicity in some women. The most widely used TOP2i include anthracyclines (AC) Doxorubicin (DOX), Daunorubicin (DNR), Epirubicin (EPI), and the anthraquinone Mitoxantrone (MTX). It is unclear whether women would experience the same adverse effects from all drugs in this class, or if specific drugs would be preferable for certain individuals based on their cardiotoxicity risk profile. To investigate this, we studied the effects of treatment of DOX, DNR, EPI, MTX, and an unrelated monoclonal antibody Trastuzumab (TRZ) on iPSC-derived cardiomyocytes (iPSC-CMs) from six healthy females. All TOP2i induce cell death at concentrations observed in cancer patient serum, while TRZ does not. A sub-lethal dose of all TOP2i induces limited cellular stress but affects calcium handling, a function critical for cardiomyocyte contraction. TOP2i induce thousands of gene expression changes over time, giving rise to four distinct gene expression response signatures, denoted as TOP2i early-acute, early-sustained, and late response genes, and non-response genes. There is no drug- or AC-specific signature. TOP2i early response genes are enriched in chromatin regulators, which mediate AC sensitivity across breast cancer patients. However, there is increased transcriptional variability between individuals following AC treatments. To investigate potential genetic effects on response variability, we first identified a reported set of expression quantitative trait loci (eQTLs) uncovered following DOX treatment in iPSC-CMs. Indeed, DOX response eQTLs are enriched in genes that respond to all TOP2i. Next, we identified 38 genes in loci associated with AC toxicity by GWAS or TWAS. Two thirds of the genes that respond to at least one TOP2i, respond to all ACs with the same direction of effect. Our data demonstrate that TOP2i induce thousands of shared gene expression changes in cardiomyocytes, including genes near SNPs associated with inter-individual variation in response to DOX treatment and AC-induced cardiotoxicity.
Participants will receive JNJ-79635322. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
An anti-Her 3 antibody drug conjugate has the structure Ab- (L-M-D)  p  (I), wherein L and M are linker units, D is a cytotoxic drug, P represents the average number of linkages, ab is an anti-Her 3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region comprising amino acid sequences as set forth in SEQ ID NOs: 1. SEQ ID NO:2 and SEQ ID NO:3, HCDR1, HCDR2 and HCDR3, the light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 4. SEQ ID NO:5 and SEQ ID NO: LCDR1, LCDR2 and LCDR3 as shown in fig. 6. A pharmaceutical composition comprising an anti-Her 3 antibody drug conjugate of the structure of formula (I), an isomer thereof, a pharmaceutically acceptable salt thereof or a mixture thereof, and a pharmaceutically acceptable carrier or excipient. The antibody drug conjugate or composition can be used for preparing drugs for treating and/or preventing Her3 mediated diseases or conditions.
This is a natural history study with a cross-sectional design of Moebius syndrome (MIM 157900), a heterogeneous developmental disorder defined as a congenital, non-progressive facial weakness with limited abduction of one or both eyes, often associated with additional features such as other cranial nerve dysfunction, craniofacial, skeletal and limb deformities, as well as intellectual or behavioral impairments. In this study we will attempt to characterize the clinical phenotype of Moebius and associated congenital facial weakness syndromes, collect thorough information on possible prenatal environmental exposures and use genetic studies, including whole exome sequencing, on DNA from patients and family members of patients to identify disease-causing genes. We will also conduct brain magnetic resonance- and diffusion tensor imaging- studies in these patients in order to explore brainstem and cranial nerve structure and associated white matter tract anomalies. Through this combined clinical, molecular and imaging approach, we anticipate that phenotype-genotype correlations will be revealed. These results will lead to new insights into the clinical definition of these conditions, molecular pathways, and potential networks involved in the pathogenesis of facial weakness and associated multisystem dysmorphogenesis. Our population will consist of patients, ages 2 to 80 years, inclusive of any gender, race, or ethnic group, with congenital facial palsy, isolated or combined with other congenital anomalies, and their families. We will continue to recruit approximately 24 probands each year, ages 2 to 80 years, inclusive of any gender, race, or ethnic group, and their parents and unaffected family members for a total of 72 patients/families. In most cases, patients will be referred through the Moebius Syndrome Foundation, a patient organization with a current membership of 2000 people in its database, 1400 of whom have been diagnosed with Moebius syndrome. Outcome measures will include the results from a battery of clinical evaluations, including ophthalmology, audiology, neurology, psychiatry, and rehabilitative medicine. Patients will also undergo neurocognitive and autism screening assessments, electromyography/nerve conduction, and blink reflex studies. Imaging and genetic studies will provide the most robust data for analysis in this study. A skin biopsy may be performed on some patients in order to culture fibroblasts for additional biochemical, cell biological, and molecular analyses.
NEW MATERIAL:A peptide having Leu-Lys-Pro skeleton. EXAMPLE:A peptide having the formula, H-Leu-Lys-Pro-OH. USE:Useful for an angiotensin-transferring enzyme inhibitor, as preventive or therapeutic agent, or antihypertensive agent of hypertension, etc., with a slight side effect. Said inhibitor is preferably administrated orally. PREPARATION:At first, a protein (preferably derived from dried bonito, etc.) is mixed in hot water to homogenize and thermolysin is added, then hydrolyzing reaction is performed at 10-85 deg.C for 0.1-48hr. Next, said hydrolyzed solution is centrifuged and concentrated, and then purified by subjecting to high- performance liquid chromatography, etc.
Active Duodenal Ulcer —The recommended oral dosage for adults is 300 mg once daily at bedtime. An alternative dosage regimen is 150 mg twice daily.

Maintenance of Healed Duodenal Ulcer —The recommended oral dosage for adults is 150 mg once daily at bedtime.

Gastroesophageal Reflux Disease —The recommended oral dosage in adults for the treatment of erosions, ulcerations, and associated heartburn is 150 mg twice daily.

Active Benign Gastric Ulcer—The recommended oral dosage is 300 mg given either as 150 mg twice daily or 300 mg once daily at bedtime. Prior to treatment, care should be taken to exclude the possibility of malignant gastric ulceration.

Each mL of nizatidine oral solution contains 15 mg of nizatidine. In adults, nizatidine oral solution may be substituted for any of the above indications using equivalent doses of the oral solution.

Pediatric Dosing—Each mL of oral solution contains 15 mg of nizatidine. Nizatidine oral solution is indicated for pediatric patients 12 years of age or older. For pediatric patients 12 years of age and older, the dosage of nizatidine is 150 mg b.i.d. (2 tsp, b.i.d.)

The following dosage recommendations are provided:

Erosive Esophagitis—For pediatric patients 12 years or older, the dosage is 150 mg b.i.d. (300 mg/d). The maximum daily dose for nizatidine PO is 300 mg/d. The dosing duration may be up to eight weeks.

Gastroesophageal Reflux Disease— For pediatric patients 12 years or older, the dosage is 150 mg b.i.d. (300 mg/d). The maximum daily dose for nizatidine PO is 300 mg/d. The dosing duration may be up to eight weeks.

Dosage Adjustment for Patients With Moderate to Severe Renal Insufficiency—The dose for patients with renal dysfunction should be reduced as follows:

Some elderly patients may have creatinine clearances of less than 50 mL/min, and, based on pharmacokinetic data in patients with renal impairment, the dose for such patients should be reduced accordingly. The clinical effects of this dosage reduction in patients with renal failure have not been evaluated.

Based on the pharmacokinetic data in elderly patients with renal impairment, pediatric patients with creatinine clearances less than 50 mL/min, should have their dose of nizatidine reduced accordingly. The clinical effects of this dose reduction in pediatric patients with renal failure have not been evaluated.
BACKGROUND: There is continuous growth of combined liver-kidney transplantation (CLKTx) numbers with remarkable outcomes, especially among patient with liver cirrhosis and end-stage renal disease. The aim was to present a single center experience.
METHODS: Twenty patients (9 males) with a mean age of 48 (range: 20-62) years underwent CLKTx from 2005 to 2022. Indications were polycystic liver and kidney diseases (ADPKD) in 12 cases, cirrhosis due to hepatitis (4 patients), and 1 case of amyloidosis, alcoholic liver disease, nonalcoholic steatosis, and congenital hepatic fibrosis with concomitant glomerulonephritis. After hepatectomy, half of the patients had orthotopic liver transplantation with piggy-back technique, and the other had conventional technique. All but 1 recipient had biliary end-to-end anastomosis. 3 patients had preemptive kidney graft transplantation. 4 underwent simultaneous right-side nephrectomy due to volume of the right kidney. Kidney was transplanted from the separate incision after abdominal closure with typical anastomoses. Tacrolimus, mycophenolate mofetile, basiliximab, and steroids were applied for all recipients.
RESULTS: Mean follow-up was 57.7 ± 54 months. No primary non-function of the grafts occurred. Delayed kidney graft function (DGF) occurred in 8 patients. Three-month, 1-year, and 5-year cumulative survival rates were: 90%, 80%, and 72% respectively. None of the patients required retransplantation, and 1 recipient returned to hemodialysis 19 months after transplantation. Preemptive kidney transplantation and simultaneous right-side nephrectomy were not significant for DGF and recipient survival. No deaths within the first year occurred in piggy-back technique.
CONCLUSIONS: CLKTx is safe and effective in the treatment of both liver and kidney failure.
Drawing on interviews with 31 2SLGBTQ+ people labeled with developmental and/or intellectual disabilities, this exploratory study focuses on participants' experiences navigating mainstream queer social spaces. The current study is an explorative qualitative view at the intersection of the 2SLGBTQ+ and disability community. There is a call for more inclusive spaces for people with disabilities within queer social areas. Although queer spaces attempt to be free and inclusive, many have inaccessible activities and locations. The findings depict that individuals with lived experiences are not often represented in the 2SLGBTQ+ community due to a lack of inclusion. Participants highlighted feelings of rejection as people with disabilities were not represented in many 2SLGBTQ+ focused groups or organizations. The current paper calls attention to creating more inclusive intersectional spaces to promote inclusivity and ensure people with disabilities have the opportunity to contribute through an active role in the 2SLGBTQ+ community.
This study was approved by the University of Victoria Human Research Ethics Board (Protocol Number 17-167) and all participants provided their informed written consent prior to participating in this study. In order to reduce the placebo effect, the participants were randomly divided into the experimental and control groups. Participants from both the experimental and control groups received a total of three neuropsychological assessments over a three month period (i.e. baseline, 7 weeks, 11 weeks). Considering that an essential methodological component of the training studies is the use of standardized neuropsychological tests, validated and reliable measures such as STROOP TEST, DIGIT SPAN TEST, TRAIL MAKING TEST, VERBAL FLUENCY TESTS, CALIFORNIA VERBAL LEARNING TEST Second Edition (i.e., standard and alternate forms), were used at different time points. Each assessment was 50-60 minutes in duration and was administered by an expert neuropsychology resident. The first assessment was administered at baseline . Then, the experimental group underwent seven weeks of perceptual cognitive training, while the control group completed seven weeks without formal training. The treatment for the PCT group consisted of 14 sessions of training each lasting 25-30 min, twice per week for seven weeks. After the seven-week time period, a second neuropsychological assessment was performed on both groups. After eleven weeks, a follow-up assessment was conducted to verify whether the benefits of cognitive training endure over time.
The invention discloses a Chinese herb extract and its application in the preparation of a medicine for treating ovarian cysts. The Chinese herb extract is prepared from Mertensia maritime, Gentiana scabra Bunge and Kalimeris lautureana. The Chinese herb extract is prepared by the following steps: crushing raw materials and sieving, extracting by a supercritical carbon dioxide extraction technology, collecting volatile oil, extracting by using ethanol, filtering, collecting an extracting solution, condensing and drying, adding water and carrying out reflux extraction, filtering, condensing an extracting solution, passing through macroporous resin, eluting with water, eluting with an ethanol solution, condensing and drying so as to obtain the target Chinese herb extract. The Chinese herb extract can eliminate or minimize hysteromyoma and ovarian cysts and has remarkable effects. Effective rate of the Chinese herb extract can reach 99%. The Chinese herb extract has advantages of rapid effectiveness, low cost, high safety and little toxic and side effect. By the use of the Chinese herb extract, the purpose of simultaneously treating principal and subordinate symptoms of ovarian cysts can be achieved. The Chinese herb extract is worth of wide clinic popularization and application.
Rates of substance use disorders (SUDS) are high among military personnel and Veterans. While much research is focused on the acute care of SUDs, the risk of relapse to substance use following treatment is high and attention to continuing care is critical. New continuing care strategies targeting life-style change and improved coping mechanisms are important in facilitating maintenance of abstinence, promoting rehabilitation and functional recovery for Veterans with SUDs. Mindfulness-based relapse prevention (MBRP), a manualized treatment integrating cognitive-behavioral relapse prevention therapy with mindfulness practices, has shown promise in continuing care for SUDs. The proposed project will compare MBRP to a 12-Step Facilitation treatment as a continuing care strategy following primary treatment for SUDs. Participants will be randomized to participate in 8-weeks of weekly 90-minute, group-based MBRP or 12-Step Facilitation followed by a 10-month follow-up period with regular assessments of substance use, mood/anxiety symptoms, quality of life and functional outcomes. Two VAMC sites (Charleston and Tuscaloosa) with a history of successful collaboration will work together to recruit an adequate sample size to address the primary study questions within a 4-year period and to ensure generalizability of the results. If this trial demonstrates that MBRP promotes sustained abstinence and improved functional outcomes, this will provide a valuable treatment to facilitate rehabilitation and recovery for Veterans with SUDs.
β-arrestin2 is a versatile protein for signaling transduction in brain physiology and pathology. Herein, we investigated the involvement of β-arrestin2 in pharmacological effects of fluoxetine for depression. A chronic mild stress (CMS) model was established using wild-type (WT) and β-arrestin2-/- mice. Behavioral results demonstrated that CMS mice showed increased immobility time in the tail suspension test and forced swimming test, elevated concentrations of pro-inflammatory factors in peripheral blood, increased expression of pyroptosis-related proteins, and increased co-labeling of glial fibrillary acidic protein and Caspase1 p10 in the hippocampus compared to the CON group. Treatment with fluoxetine (FLX) ameliorated these conditions. However, compared with the β-arrestin2-/- CMS group, these results of the β-arrestin2-/- CMS + FLX group showed no significant changes. These results suggested that the above effects of FLX could be eliminated by knocking out β-arrestin2. Mass spectrometry implying that FLX promoted the binding of β-arrestin2 to the NLRP2 inflammasome of depressed mice. Subsequently, the results of the cellular experiments suggested that the 5HT2B receptor antagonist may attenuate L-kynurenine + ATP-induced cell pyroptosis by attenuating NLRP2 binding to β-arrestin2. We further found that the lack of β-arrestin2 eliminated the anti-pyroptosis effect of fluoxetine. In conclusion, β-arrestin2 is an essential protein for fluoxetine to alleviate pyroptosis in the hippocampal astrocytes of CMS mice. Mechanistically, we found that the 5-HT2BR-β-arrestin2-NLRP2 axis is vital for maintaining the antidepressant effects of fluoxetine.
Patients randomized to the control group will also receive an activity tracker (like the intervention group). We will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.
PCT No. PCT/US94/08473 Sec. 371 Date Apr. 4, 1995 Sec. 102(e) Date Apr. 4, 1995 PCT Filed Jul. 26, 1994 PCT Pub. No. WO95/03335 PCT Pub. Date Feb. 2, 1995This invention is directed to a therapeutic strategy, involving (1) identification of alternative alleles of genes coding for proteins vital for cell viability or cell growth and the loss of one of these alleles in cancer cells due to loss of heterozygosity (LOH) and (2) the development of inhibitors with high specificity for the single remaining alternative allele of the vital gene retained by the cancer cell after LOH. The inhibitors of this invention are specific for one alternative allele of a gene that codes for a protein vital to cell viability or cell growth. The targeted gene has two alternative alleles in which the inhibitors of this invention block only the one alternative allele still present in the cancer cells. Exposure to the inhibitor inhibits or kills cancer cells which have undergone LOH. Protein is still capable of being expressed in the normal cells exposed to the inhibitor by the unblocked alternative allele. This differential effect of the inhibitor on cancer cells and normal cells accounts for the high therapeutic index of the inhibitors of this invention when used as antineoplastic agents.
Hawthorns belong to rosaceous plants and have a long health care and medicinal history in China. The hawthorn fruits are rich in total flavonoids. The total flavonoids have various pharmacological and health care functions of reducing blood pressure and blood fat and resisting tumors, diabetes mellitus and complications thereof. How to improve the extraction rate of the total flavonoids in the hawthorns attracts more attentions of people. Cellulase can hydrolyze cellulose of cell walls of the hawthorns into water-soluble sugars and the cell walls of the hawthorns, treated by the cellulase, are hydrolyzed and broken, thus being beneficial to dissolution of flavonoid compounds in cells. Ultrasonic vibration can lead to motion of substances in the cells to enable the cytoplasm to flow and the cells to shake, thus thinning the cell walls. Ultrasonic vibration is beneficial to interinfiltration in solvents and plant cells, thus increasing dissolution of active ingredients in the solvents. Therefore, by combining the cellulase enzymolysis method and the ultrasonic extraction method, the advantages of the two methods can complement each other and more flavonoid substances in the hawthorns can be extracted under the moderate and controllable conditions.